Sonata Therapeutics Inc. and the Champalimaud Foundation have announced a research collaboration for the development of Sonata’s SNT-3012 for the treatment of pancreatic and colorectal cancers.
Monopar Therapeutics Inc. has released promising preclinical imaging data of a therapeutic radioisotope bound to its proprietary urokinase plasminogen activator receptor (uPAR)-targeting agent, MNPR-101.
Crossbow Therapeutics Inc. has nominated its first development candidate, CBX-250, a first-in-class, potent and specific T-cell engager (TCE) for the treatment of myeloid leukemia. CBX-250 targets a cathepsin G (CTSG) peptide-human leukocyte antigen (pHLA) complex abundantly expressed on leukemic cells, but not on normal cells.
Haisco Pharmaceutical Group Co. Ltd. has prepared proteolysis targeting chimera (PROTAC) compounds comprising a cereblon ligase-binding moiety coupled to an EGFR (HER1; erbB1)-targeting moiety through a linker.
Shanghai Jemincare Pharmaceuticals Co. Ltd. has disclosed nitrogen-containing heterocyclic compounds acting as ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors potentially useful for the treatment of cancer.
Chia Tai Tianqing Pharmaceutical Group Co. Ltd. has identified new tricyclic compounds acting as GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.
Eilean Therapeutics LLC has announced the acquisition of Ness Therapeutics Inc. in an all-equity transaction, including Ness’ best-in-class tyrosine-protein phosphatase non-receptor type 2 (PTPN2) inhibitors with application in immuno-oncology.
Biomunex Pharmaceuticals SAS has signed an exclusive license and exploitation agreement with Institut Curie for the development of a new class of antibodies.
Scientists from Sun Yat-sen University Cancer Center (SYSUCC) and affiliated organizations have reported data from a study that assessed the role of discs large-associated protein 5 (DLGAP5) in lung adenocarcinoma (LUAD).
RSS
